<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJS</journal-id><journal-title-group><journal-title>Hans Journal of Surgery</journal-title></journal-title-group><issn pub-type="epub">2168-5584</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJS.2020.92002</article-id><article-id pub-id-type="publisher-id">HJS-34506</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJS20200200000_42817432.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胰腺癌诊疗进展
  Advances in Diagnosis and Treatment of Pancreatic Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>屠</surname><given-names>松</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>石</surname><given-names>景明</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>河西学院附属张掖人民医院，普外二科，甘肃 张掖</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>13</day><month>03</month><year>2020</year></pub-date><volume>09</volume><issue>02</issue><fpage>5</fpage><lpage>12</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   胰腺癌是恶性程度很高的肿瘤，占恶性肿瘤致死原因的第7位。其起病隐匿，发现时一般属于中晚期，预后较差。早发现及早治疗是提高预后的关键。本文对胰腺癌诊断及治疗方面的进展进行综述。 Pancreatic cancer is high degree of malignancy tumor, accounting for the 7th leading cause of death from malignant tumors. Because of its insidious onset, and it is generally in the middle and late stages when found, with a poor prognosis. Early detection and treatment are the key to im-prove the prognosis. This article reviews the advances in diagnosis and treatment of pancreatic cancer. 
 
</p></abstract><kwd-group><kwd>胰腺癌，诊断，治疗，进展, Pancreatic Cancer</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd><kwd> Advance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胰腺癌诊疗进展<sup> </sup></title><p>闫鹏，屠松，石景明</p><p>河西学院附属张掖人民医院，普外二科，甘肃 张掖</p><p>收稿日期：2020年2月21日；录用日期：2020年3月6日；发布日期：2020年3月13日</p><disp-formula id="hanspub.34506-formula3"><graphic xlink:href="//html.hanspub.org/file/1-2280202x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>胰腺癌是恶性程度很高的肿瘤，占恶性肿瘤致死原因的第7位。其起病隐匿，发现时一般属于中晚期，预后较差。早发现及早治疗是提高预后的关键。本文对胰腺癌诊断及治疗方面的进展进行综述。</p><p>关键词 :胰腺癌，诊断，治疗，进展</p><disp-formula id="hanspub.34506-formula4"><graphic xlink:href="//html.hanspub.org/file/1-2280202x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2280202x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-2280202x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>胰腺癌是恶性肿瘤中死亡率较高的肿瘤，一般起病隐匿，患者发现时多已属于晚期，易出现肝脏等远处器官的转移，失去根治性手术的机会。GLOBOCAN2018的数据报道，在世界范围内，2018年预计胰腺癌新发患者458,918人，死亡患者432,242人。胰腺癌患者年龄标准化发病率北美洲男性为8.7/100,000，女性为6.5/100,000；东亚男性为7.0/100,000，女性为4.8/100,000。胰腺癌是肿瘤导致死亡原因的第7位 [<xref ref-type="bibr" rid="hanspub.34506-ref1">1</xref>]。到目前为止，已经确定了一些胰腺癌的危险因素，如吸烟、肥胖、遗传、糖尿病、饮食、缺乏运动等，但确切病因仍未充分阐明 [<xref ref-type="bibr" rid="hanspub.34506-ref2">2</xref>]。本文就胰腺癌的诊治最新进展做文献复习与综述。</p></sec><sec id="s4"><title>2. 胰腺癌的诊断</title><sec id="s4_1"><title>2.1. 影像学检查及影像引导下穿刺</title><p>胰腺癌之所以死亡率高，与其早期检出率低有明显关系。为改善患者生存时间，早期诊断至关重要。常用的诊断方法包括：计算机断层显像(computed tomography, CT)、核磁共振(magnetic resonance imaging, MRI)、磁共振胆胰管成像(magnetic resonance cholangiopancreatography, MRCP)、超声内镜下细针抽吸(endoscopic ultrasound fine-needle aspiration, EUS-FNA)或者活检。CT在胰腺癌诊断中有重要价值，但MRCP能显示胰腺实质和胆胰管的形态变化，更有助于早期发现肿瘤。在CT和EUS不能完全诊断的特殊情况下，也可使用正电子发射断层扫描(positron emission tomography, PET)技术。胰腺成像新技术，包括双能、低管电压CT技术、迭代重建CT算法、功能性MRI方法和混合正电子发射断层扫描/磁共振成像技术等，这些技术有望在不久的将来得到广泛应用，并将在胰腺癌成像中显示出优异的性能 [<xref ref-type="bibr" rid="hanspub.34506-ref3">3</xref>]。</p><sec id="s4_1_1"><title>2.1.1. 双能和低管电压CT技术</title><p>CT在胰腺癌诊断和分期方面有一定的优势，但对于直径小于2 cm肿瘤的检测仍具有一定的困难 [<xref ref-type="bibr" rid="hanspub.34506-ref4">4</xref>]。而双能或低管电压CT技术能改善胰腺癌和正常组织之间的对比噪声比，增加肿瘤的检出率 [<xref ref-type="bibr" rid="hanspub.34506-ref5">5</xref>]。用双能CT进行腹部检查时，由于病灶与背景对比度的改善，增强的病灶或血管在碘图上更加明显。碘图不仅有助于鉴别高密度、囊性病变或血肿与强化病灶，而且有助于明确肠缺血程度 [<xref ref-type="bibr" rid="hanspub.34506-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.34506-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.34506-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.34506-ref9">9</xref>]。材料特异性碘图像可将低衰减肿瘤与高衰减囊肿区分开来，有利于等衰减肿瘤(如胰腺肿块和腹膜疾病)的发现，从而为影像学引导治疗确定靶点。双能CT是一种创新的成像技术，可提高CT诊断效能 [<xref ref-type="bibr" rid="hanspub.34506-ref7">7</xref>]。低管电压CT技术增加了碘的X射线吸收，改善了正常胰腺实质和胰周血管的对比强化，最大限度地使典型的乏血供胰腺癌病灶强化 [<xref ref-type="bibr" rid="hanspub.34506-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.34506-ref10">10</xref>]。双能CT和低管电压技术可以提高对胰腺小肿瘤或等衰减肿瘤的检出率 [<xref ref-type="bibr" rid="hanspub.34506-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.34506-ref10">10</xref>]。</p></sec><sec id="s4_1_2"><title>2.1.2. 迭代重建CT</title><p>最近发展起来一种基于迭代重建算法的CT降噪新方法，在降低图像噪声方面具有重要的作用，可用于高空间分辨率的胰腺CT成像，可提供高质量、1~2 mm的薄层CT图像 [<xref ref-type="bibr" rid="hanspub.34506-ref3">3</xref>]。Yamamura S等人 [<xref ref-type="bibr" rid="hanspub.34506-ref11">11</xref>] 对18例局部进展期胰腺癌患者进行了CT检查，应用了低管电压和迭代重建技术，研究显示应用该技术可显著提高胰腺动态CT的图像质量。Yoshifumi Noda等人 [<xref ref-type="bibr" rid="hanspub.34506-ref12">12</xref>] 前瞻性地评估了胰腺恶性肿瘤在80 KV (峰值)管电压设置和低碘剂量下CT的增强图像质量、辐射剂量和可检出性，结论提示低管电压与自适应统计迭代重建技术80 KV设置的胰腺CT和400 mg/kg碘的对比物负荷，有利于降低碘剂量，同时保持胰腺恶性肿瘤的图像质量和可检出性。</p></sec><sec id="s4_1_3"><title>2.1.3. 功能性MRI</title><p>虽然MRI对局灶性病变具有良好的软组织对比优势，但是小的胰腺癌病灶可能缺乏经典的MRI影像学特征，常规MRI可能无法检测 [<xref ref-type="bibr" rid="hanspub.34506-ref3">3</xref>]。定时动态增强磁共振成像所获得的灌注参数有助于胰腺实性病变的鉴别诊断和预后判断。Jae Hyun Kim等人的研究显示定时动态增强MRI的相关灌注参数速率常数(K<sub>ep</sub>)、 体积转移系数(K<sup>trans</sup>)、60秒内浓度曲线下的初始面积(iAUC)等在胰腺癌患者的肿瘤组织和癌旁组织中有显著的差异 [<xref ref-type="bibr" rid="hanspub.34506-ref13">13</xref>]。此类功能性的MRI方法有助于提高胰腺癌的检出率。</p></sec><sec id="s4_1_4"><title>2.1.4. 混合正电子发射断层扫描/磁共振成像技术</title><p>正电子发射断层成像(PET)结合磁共振成像(MRI)是一种混合技术，近年来作为一种潜在的肿瘤成像工具引起了人们的兴趣 [<xref ref-type="bibr" rid="hanspub.34506-ref14">14</xref>]。该技术可以同时从MRI成像中获取功能/解剖信息和PET图像中的分子/代谢信息。PET/MRI应用广泛，在肿瘤领域可以描述肿瘤特征和分期。利用PET/MRI提供的解剖和功能信息，可以更好地了解特定的生物物理和代谢变化 [<xref ref-type="bibr" rid="hanspub.34506-ref15">15</xref>]。有研究者将PET/MRI成像用于评估局部晚期胰腺癌患者的分期，以及评估接受新辅助化学或放射治疗的胰腺癌患者治疗前后的肿瘤变化 [<xref ref-type="bibr" rid="hanspub.34506-ref3">3</xref>]。相较于普通CT及MRI可以了解到肿瘤的代谢变化。</p></sec><sec id="s4_1_5"><title>2.1.5. 超声内镜引导下细针活检术(Endoscopic Ultrasound-Guided Fine Needle Biopsy, EUS-FNB)</title><p>超声内镜下细针穿刺活检技术(EUS-FNB)是一项较新的技术，对操作者有较高的要求。Ji Young Bang等人 [<xref ref-type="bibr" rid="hanspub.34506-ref16">16</xref>] 研究了EUS-FNB和超声内镜下细针抽吸术(EUS-FNA)对实体肿瘤诊断率的差异。3020例患者在超声引导下进行了实体瘤(胰腺肿块71.3%，其他部位肿块28.7%)病灶取样，FNA为68.9%，FNB为31.1%。与FNA相比，FNB的诊断率显著高于FNA (92.3%和71.1%，p &lt; 0.001)。在胰腺(p &lt; 0.001)和非胰腺病变(p &lt; 0.001)中观察到FNB亦优于FNA。相较于上述影像学检查，此类穿刺活检为有创检查，一般患者先进行无创检查若疗效不佳再进行穿刺活检。</p></sec></sec><sec id="s4_2"><title>2.2. 分子标记物检测</title><p>糖类抗原CA19-9是检测胰腺癌最常用的肿瘤标记物。一项Meta分析 [<xref ref-type="bibr" rid="hanspub.34506-ref17">17</xref>] 共纳入符合纳入标准的21项研究共3497名病例，结果显示CA19-9检测胰腺癌的敏感性为75.4% (95% CI: 73.4%~77.4%)；特异性为77.6% (95% CI: 75.4%~79.7%)。但胃肠道肿瘤、胆道梗阻、慢性胰腺炎等疾病也会出现CA19-9升高。分子标记物作为无创检查的手段之一，有很好的临床应用前景，但目前大多仍处于基础研究阶段，临床主要依靠影像学检查确诊，且单一的分子标记物诊断效能较低，需要联合多种分子标记物检测试剂盒有望提高其诊断效能。</p><sec id="s4_2_1"><title>2.2.1. 循环micro-RNAs检测</title><p>MicroRNAs属于一个小的、非编码的RNA家族，其在转录后水平上调节基因表达，主要抑制基因和蛋白质的表达，在包括细胞凋亡、细胞增殖和分化等在内的各种发育、代谢和细胞过程中起着至关重要的作用 [<xref ref-type="bibr" rid="hanspub.34506-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.34506-ref19">19</xref>]。目前循环microRNAs检测在多种肿瘤的早期诊断和预后中都有应用。XUEFEI TIAN等人 [<xref ref-type="bibr" rid="hanspub.34506-ref20">20</xref>] 对17例胰腺癌转移并吉西他滨耐药的患者在拉帕替尼加卡培他滨治疗过程中检测了循环microRNAs。分析与EGFR1和HER2信号通路相关的miRNAs (miR-21、miR-210、miR-221和miR-7)表达谱，并对其表达进行了比较。结果显示在拉帕替尼和卡培他滨治疗开始后3周，血中miR-221水平的升高可能预示着胰腺癌患者治疗失败以及临床获益率低。</p></sec><sec id="s4_2_2"><title>2.2.2. 循环肿瘤细胞(Circulating Tumor Cells, CTCs)检测</title><p>循环肿瘤细胞(CTCs)是从实体肿瘤中脱落的罕见细胞，在大多数癌症患者的血液中数量极低 [<xref ref-type="bibr" rid="hanspub.34506-ref21">21</xref>]。它是原发肿瘤和继发肿瘤之间的桥梁，是肿瘤转移和自我种植的种子 [<xref ref-type="bibr" rid="hanspub.34506-ref22">22</xref>]。CTCs检测是液体活检中的重要部分，也是目前肿瘤诊断与评估疗效的很有价值的方法。KATARINA KOLOSTOVA等人 [<xref ref-type="bibr" rid="hanspub.34506-ref23">23</xref>] 报道了两例分别怀疑肺癌和胰腺癌的患者，前者CT发现左肺上叶60 &#215; 4.0 mm占位，反复支气管镜检查和痰培养均未发现恶性细胞；后者有2个月的消化道不适症状，CT发现直径约180 mm胰头占位，经内镜活检未发现任何癌细胞。取两者的外周血进行分离，最终从患者血液中分离出循环肿瘤细胞(CTCS)，使患者得到了确诊。</p></sec><sec id="s4_2_3"><title>2.2.3. 甲基化DNA检测</title><p>DNA甲基化是一种通过控制DNA序列的获取而参与调控基因表达的化学修饰。在哺乳动物中，DNA甲基化参与控制遗传密码的表达，DNA甲基化异常与多种疾病的发生发展有关，包括肿瘤 [<xref ref-type="bibr" rid="hanspub.34506-ref24">24</xref>]。Joo Mi Yi 等人 [<xref ref-type="bibr" rid="hanspub.34506-ref25">25</xref>] 使用一种全基因组的转录方法鉴定胰腺癌细胞株中新的肿瘤特异性DNA甲基化改变，发现了两个新基因BNC1和ADAMTS1，它们在胰腺癌中表现出高频率甲基化。使用纳米颗粒使甲基化技术在42例胰腺癌患者血清中检测到了这种DNA甲基化的改变。最终发现BNC1和ADAMTS1的启动子DNA甲基化是检测早期胰腺癌的潜在生物标志物。因此检测血清循环DNA中这些基因的启动子甲基化状态是早期发现胰腺癌的一种很有前途的方法。</p></sec><sec id="s4_2_4"><title>2.2.4. 外泌体检测</title><p>外泌体是双层脂质包裹的细胞外小泡，含有蛋白质和核酸。它们由所有细胞分泌并在血液中循环。目前还缺乏对循环中癌细胞衍生的外泌体的特异性检测和分离方法。Sonia A. Melo等人 [<xref ref-type="bibr" rid="hanspub.34506-ref26">26</xref>] 通过质谱分析鉴定了一种细胞表面蛋白多糖-1 (GPC1)，它富集于癌细胞衍生的外泌体中，并且在胰腺癌患者的血清中检测出的GPC1 (+)循环外泌体具有绝对的特异性和敏感性，能将正常人和良性胰腺疾病患者与早期和晚期胰腺癌患者区别开来。他们认为GPC1(+)循环外泌体可作为一种潜在的无创诊断和筛查工具，用于检测早期胰腺癌。</p></sec></sec></sec><sec id="s5"><title>3. 胰腺癌的治疗进展</title><sec id="s5_1"><title>3.1. 手术</title><p>手术仍然是胰腺癌根治性治疗的主要手段。随着腹腔镜技术及机器人手术的进步和临床应用日趋广泛，目前腹腔镜下或机器人辅助腹腔镜下胰十二指肠切除术、胰体尾切除术等手术正在逐步开展。与传统的开放手术相比，其具有恢复时间快、住院时间短等优势，但花费较高 [<xref ref-type="bibr" rid="hanspub.34506-ref27">27</xref>]。当然，胰腺癌可切除状态的评估、是否R0切除、切缘状态、血管侵犯程度、是否血管置换、邻近器官切除、消化道重建、是否扩大根治以及术者的外科手术操作水平等因素均可能对患者的预后有影响。近来，随着手术辅助技术的提高，尤其术中超声、术中冰冻切片、术中荧光肿瘤染色等方法的应用对于提高手术根治率起到了一定的作用。</p><sec id="s5_1_1"><title>3.1.1. 术中超声检查</title><p>腹腔镜或开放手术过程中使用超声检查可以确定肿瘤的边界、评估可切除性以及鉴别可能的转移灶 [<xref ref-type="bibr" rid="hanspub.34506-ref28">28</xref>]。C. de Werra等人 [<xref ref-type="bibr" rid="hanspub.34506-ref29">29</xref>] 报道34例胰头癌患者在腹腔镜或开腹手术中使用了超声检查，22例术中检查与术前CT或MRI的结果不完全符合，仅有12例患者能进行胰十二指肠切除术。术中超声能弥补术前CT或MRI对病灶界限、周围组织侵犯程度、微小转移灶、淋巴结转移、可否切除等病情评估的不足。</p></sec><sec id="s5_1_2"><title>3.1.2. 术中冰冻切片</title><p>术中冰冻组织切片是一种能够快速明确病理诊断的方法，而且能够提示手术切缘情况 [<xref ref-type="bibr" rid="hanspub.34506-ref28">28</xref>]。一项研究 [<xref ref-type="bibr" rid="hanspub.34506-ref30">30</xref>] 表明冰冻切片对组织学诊断的敏感性为80%，特异性为100%，阳性预测值为100%，阴性预测值为50%，总准确率为83%。术中冰冻切片分析确定最终切缘状态的敏感性为33%，特异性为100%，阳性预测值为100%，阴性预测值为97%，总准确率为97%。冰冻切片分析无假阳性结果。所以术中冰冻切片也是胰腺癌手术中提高疗效的必要手段。</p></sec><sec id="s5_1_3"><title>3.1.3. 荧光染色</title><p>荧光引导手术已成为一种新的术中辅助外科医生可视化肿瘤、前哨淋巴结等的手术方式 [<xref ref-type="bibr" rid="hanspub.34506-ref28">28</xref>]。原理是用近红外光照射荧光染料标记过的肿瘤或淋巴结组织后能够显示荧光，进而将其与正常组织区分开来。目前只有吲哚青绿和亚甲基蓝这两种非特异性的近红外荧光染料获得批准用于临床，主要用于前哨淋巴结定位、胆管成像和输尿管显影等 [<xref ref-type="bibr" rid="hanspub.34506-ref31">31</xref>]。Shuya Yano等学者 [<xref ref-type="bibr" rid="hanspub.34506-ref32">32</xref>] 认为精确的荧光引导手术治疗胰腺癌会大大改善患者的预后。他们将人类胰腺癌移植到NOD/SCID小鼠皮下，生长一段时间后再将其植入转基因RFP裸鼠胰腺体尾部建立人源化胰腺肿瘤动物荧光模型。用不同的荧光物质标记肿瘤细胞和基质细胞，在手术中用荧光显微镜成像，可以确定肿瘤的切除范围和切缘，取得了较好的手术效果。</p></sec></sec><sec id="s5_2"><title>3.2. 化疗</title><p>目前胰腺癌的一线化疗方案包括FOLFIRINOX、吉西他滨联合紫杉醇、吉西他滨联合替吉奥、吉西他滨或替吉奥单药等。虽然化疗对改善预后有一定的作用，但治疗效果仍不尽人意。Tetsuhito Muranaka等人 [<xref ref-type="bibr" rid="hanspub.34506-ref33">33</xref>] 的一项不可切除胰腺癌化疗效果研究将FOLFIRINOX (奥沙利铂联合伊立替康及氟尿嘧啶)方案和GnP (吉西他滨联合紫杉醇)方案进行了对比，纳入患者38例，FOLFIRINOX方案化疗组(16例)缓解率为6.3%，GnP化疗组(22例)缓解率为40.9%；中位无进展时间FOLFIRINOX组3.7月(95% CI, 3.0~4.5)，GnP组6.5月(95% CI, 6.2~6.9)，两组有统计学差异(P = 0.031)。</p></sec><sec id="s5_3"><title>3.3. 放疗</title><sec id="s5_3_1"><title>3.3.1. 放射性粒子植入</title><p>一项近年的进展期胰腺癌碘125粒子植入近距离放疗后患者生存率的meta分析中，共纳入23项研究(824名患者的数据)，结果显示碘125粒子植入近距离放疗后胰腺癌患者的生存期为9个月，而碘125粒子植入近距离放疗联合其他治疗方法患者的生存率约为12个月 [<xref ref-type="bibr" rid="hanspub.34506-ref34">34</xref>]。放射性粒子植入联合化疗或其他治疗方法对延长进展期胰腺癌患者的生存率有一定的作用。</p></sec><sec id="s5_3_2"><title>3.3.2. 体外放疗及放化疗联合</title><p>体外放疗包括立体定向放疗、调强放疗等，一般要在术前或者术后联合化疗。一项研究对24例不可切除或R1切除的胰腺癌患者进行了同步放化疗，放疗中位剂量为60 Gy，化疗用吉西他滨单药(每周50 mg/m<sup>2</sup>)，2年生存率为39%，3年生存率为8.6%；2年无病生存率为32.5%，3年无病生存率为12.2% [<xref ref-type="bibr" rid="hanspub.34506-ref35">35</xref>]。Ningyi Ma等人 [<xref ref-type="bibr" rid="hanspub.34506-ref36">36</xref>] 的一项胰腺癌术后同步放化疗研究中，61例胰腺癌患者术后进行了辅助放疗，其中术后同步放化疗55例，单纯放疗6例。结果显示中位总生存率和疾病无进展生存率分别为27.4个月和16.7个月。同步放化疗和区域动脉灌注化疗是胰腺癌患者术后总生存率的独立的预测因子。</p></sec></sec><sec id="s5_4"><title>3.4. 分子靶向治疗</title><p>研究证实胰腺癌的发生发展与许多基因的突变有关，最常见的是KRAS、CDK2NA、TP53、DPC4/SMAD4等基因突变，突变频率分别为90%、90%、75%~90%、50% [<xref ref-type="bibr" rid="hanspub.34506-ref37">37</xref>]。另外Wnt、Notch、Hedgehog、TGF-β、RAS、EGFR、PI3K/Akt/mTOR等信号通路的异常也与胰腺癌的发生发展密切相关，这些通路有可能成为精准治疗的靶点 [<xref ref-type="bibr" rid="hanspub.34506-ref38">38</xref>]。厄洛替尼是一种表皮生长因子受体酪氨酸激酶抑制剂，主要用于一线联合吉西他滨治疗无法切除的胰腺癌。日本的一项厄洛替尼联合吉西他滨治疗胰腺癌的研究，纳入研究901例患者，观察了843例患者的安全性和841例患者的有效性，83.5%的患者有不良反应，52例(6.2%)患者出现间质性肺病，2例(0.2%)死亡。28周累积总生存率(overall survival, OS)为68.2%，中位无进展生存率(progression-free survival, PFS)为92天(95% CI, 86~101)。因此厄洛替尼联合吉西他滨治疗胰腺癌具有良好的安全性和有效性 [<xref ref-type="bibr" rid="hanspub.34506-ref39">39</xref>]。</p></sec><sec id="s5_5"><title>3.5. 局部治疗</title><p>胰腺癌的局部治疗包括微波消融、高强度聚焦超声消融、射频消融、氩氦刀、不可逆电穿孔等。对于不可切除晚期胰腺癌，局部消融治疗可以控制肿瘤进展，缓解患者症状。Vogl TJ等人 [<xref ref-type="bibr" rid="hanspub.34506-ref40">40</xref>] 报道了在CT引导下经皮穿刺微波治疗20例胰腺癌患者，17例恶性肿瘤病灶位于胰头(77.3%)，5例位于胰尾(22.7%)。平均肿瘤直径为30 &#177; 6 mm。技术成功率和有效率均为100%，无重大并发症发生。H.M. Strunk等人 [<xref ref-type="bibr" rid="hanspub.34506-ref41">41</xref>] 采用高强度聚焦超声治疗局部晚期胰腺癌及肿瘤相关疼痛症状患者15例(UICC III期6例，UICC IV期9例)。13例同时行标准化疗。消融后增强扫描显示肿瘤区无血液供应，3个月后平均体积减少63.8%，12例患者疼痛缓解。</p></sec><sec id="s5_6"><title>3.6. 免疫治疗</title><p>肿瘤免疫治疗包括过继细胞免疫治疗、肿瘤疫苗、免疫检查点抑制剂等，其在肿瘤治疗中所起的作用越来越重要。近年来，通过免疫检查点治疗，使用细胞毒性T淋巴细胞抗原-4 (cytotoxic T lymphocyte antigen-4, CTLA-4)和程序性死亡蛋白-1 (programmed death protein-1, PD-1)/程序性细胞死亡配体-1 (programmed cell death ligand-1, PDL-1)的阻断抗体，以及嵌合抗原受体(chimeric antigen receptor, CAR) T细胞，在临床上取得了成功 [<xref ref-type="bibr" rid="hanspub.34506-ref42">42</xref>]。对于实体肿瘤如胰腺癌等的免疫治疗还在研究阶段。2017年美国FDA快速审批通过两个CRA-T药物，分别是诺华公司生产的Kymriah和凯特公司生产的Yescarta，分别治疗复发难治25岁以下急性淋巴细胞白血病(ALL)和复发特定成人大B细胞淋巴瘤，针对的靶点均为CD19，因其频繁表达于B细胞白血病和淋巴瘤，且表达程度和水平远高于其它潜在靶点 [<xref ref-type="bibr" rid="hanspub.34506-ref43">43</xref>]。目前针对PD-1的抗体Pembrolizumab也已上市。故免疫治疗是肿瘤治疗中很有希望的一个发展方向，也有望在胰腺癌治疗中起到良好疗效。</p></sec></sec><sec id="s6"><title>4. 展望</title><p>胰腺癌是恶性肿瘤中预后较差的肿瘤，我们相信随着影像学诊断、分子标记物检测、手术以及化疗、局部消融、免疫治疗等方面药物以及技术的进步，胰腺癌的早期诊断率、手术切除率以及生存期等都能有一定的提高，并通过综合治疗能够显著改善患者的生存质量。</p></sec><sec id="s7"><title>文章引用</title><p>闫 鹏,屠 松,石景明. 胰腺癌诊疗进展Advances in Diagnosis and Treatment of Pancreatic Cancer[J]. 外科, 2020, 09(02): 5-12. https://doi.org/10.12677/HJS.2020.92002</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34506-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal, 68, 394-424. &lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.34506-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ilic, M. and Ilic, I. (2016) Epidemiology of Pancreatic Cancer. World Journal of Gastroenterology, 22, 9694-9705.  
&lt;br&gt;https://doi.org/10.3748/wjg.v22.i44.9694</mixed-citation></ref><ref id="hanspub.34506-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lee, E.S. and Lee, J.M. (2014) Imaging Diagnosis of Pancreatic Cancer: A State-of-the-Art Review. World Journal of Gastroenterology, 20, 7864-7877. &lt;br&gt;https://doi.org/10.3748/wjg.v20.i24.7864</mixed-citation></ref><ref id="hanspub.34506-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, S.H., Lee, J.M., Cho, J.Y., et al. (2011) Small (≤20 mm) Pancreatic Adenocarcinomas: Analysis of Enhancement Patterns and Secondary Signs with Multiphasic Multide-tector CT. Radiology, 259, 442-452.  
&lt;br&gt;https://doi.org/10.1148/radiol.11101133</mixed-citation></ref><ref id="hanspub.34506-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chu, A.J., Lee, J.M., Lee, Y.J., Moon, S.K., Han, J.K. and Choi, B.I. (2012) Dual-Source, Dual-Energy Multidetector CT for the Evaluation of Pancreatic Tumours. The British Journal of Radiology, 85, e891-e898.  
&lt;br&gt;https://doi.org/10.1259/bjr/26129418</mixed-citation></ref><ref id="hanspub.34506-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Goo, H.W. and Goo, J.M. (2017) Dual-Energy CT: New Horizon in Medical Imaging. Korean Journal of Radiology, 18, 555-569. &lt;br&gt;https://doi.org/10.3348/kjr.2017.18.4.555</mixed-citation></ref><ref id="hanspub.34506-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Agrawal, M.D., Pinho, D.F., Kulkarni, N.M., Hahn, P.F., Guimaraes, A.R. and Sahani, D.V. (2014) Oncologic Applications of Dual-Energy CT in the Abdomen. Radi-oGraphics, 34, 589-612. &lt;br&gt;https://doi.org/10.1148/rg.343135041</mixed-citation></ref><ref id="hanspub.34506-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">De Cecco, C.N., Darnell, A., Rengo, M., et al. (2012) Dual-Energy CT: Oncologic Applications. American Journal of Roentgenology, 199, 98-105. &lt;br&gt;https://doi.org/10.2214/AJR.12.9207</mixed-citation></ref><ref id="hanspub.34506-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">McLaughlin, P.D., Mallinson, P., Lourenco, P. and Nicolaou, S. (2015) Dual-Energy Computed Tomography: Advantages in the Acute Setting. Radiologic Clinics of North America, 53, 619-638.  
&lt;br&gt;https://doi.org/10.1016/j.rcl.2015.02.016</mixed-citation></ref><ref id="hanspub.34506-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Marin, D., Nelson, R.C., Barnhart, H., et al. (2010) Detection of Pancreatic Tumors, Image Quality, and Radiation Dose during the Pancreatic Parenchymal Phase: Effect of a Low-Tube-Voltage, High-Tube-Current CT Technique-Preliminary Results. Radiology, 256, 450-459. &lt;br&gt;https://doi.org/10.1148/radiol.10091819</mixed-citation></ref><ref id="hanspub.34506-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yamamura, S., Oda, S., Utsunomiya, D., et al. (2013) Dynamic Computed Tomography of Locally Advanced Pancreatic Cancer: Effect of Low Tube Voltage and a Hybrid Iterative Reconstruction Algorithm on Image Quality. Journal of Computer Assisted Tomography, 37, 790-796. &lt;br&gt;https://doi.org/10.1097/RCT.0b013e318296db2b</mixed-citation></ref><ref id="hanspub.34506-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Noda, Y., Kanematsu, M., Goshima, S., et al. (2014) Reduction of Iodine Load in CT Imaging of Pancreas Acquired with Low Tube Voltage and an Adaptive Statistical Iterative Reconstruction Technique. Journal of Computer Assisted Tomography, 38, 714-720. &lt;br&gt;https://doi.org/10.1097/RCT.0000000000000106</mixed-citation></ref><ref id="hanspub.34506-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J.H., Lee, J.M., Park, J.H., et al. (2013) Solid Pancreatic Lesions: Characterization by Using Timing Bolus Dynamic Contrast-Enhanced MR Imaging Assess-ment—A Preliminary Study. Radiology, 266, 185-196.  
&lt;br&gt;https://doi.org/10.1148/radiol.12120111</mixed-citation></ref><ref id="hanspub.34506-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bashir, U., Mallia, A., Stirling, J., et al. (2015) PET/MRI in Oncological Imaging: State of the Art. Diagnostics, 5, 333-357. &lt;br&gt;https://doi.org/10.3390/diagnostics5030333</mixed-citation></ref><ref id="hanspub.34506-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wehrl, H.F., Sauter, A.W., Divine, M.R. and Pichler, B.J. (2015) Combined PET/MR: A Technology Becomes Mature. Journal of Nuclear Medicine, 56, 165-168. &lt;br&gt;https://doi.org/10.2967/jnumed.114.150318</mixed-citation></ref><ref id="hanspub.34506-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Bang, J.Y., Kirtane, S., Krall, K., et al. (2018) In Memori-am-Fine Needle Aspiration, Birth-Fine Needle Biopsy: The Changing Trend in Endoscopic Ultrasound-Guided Tissue Acquisition. Digestive Endoscopy, 31, 197-202.  
&lt;br&gt;https://doi.org/10.1111/den.13280</mixed-citation></ref><ref id="hanspub.34506-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Yang, J., Li, H., Wu, Y., Zhang, H. and Chen, W. (2015) Tumor Markers CA19-9, CA242 and CEA in the Diagnosis of Pancreatic Cancer: A Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 11683-11691.</mixed-citation></ref><ref id="hanspub.34506-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Halkova, T., Cuperkova, R., Minarik, M. and Benesova, L. (2015) MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Di-agnosis and Prognosis. Gastroenterology Research and Practice, 2015, Article ID: 892903. &lt;br&gt;https://doi.org/10.1155/2015/892903</mixed-citation></ref><ref id="hanspub.34506-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Subramani, R., Gangwani, L., Nandy, S.B., Arumugam, A., Chat-topadhyay, M. and Lakshmanaswamy, R. (2015) Emerging Roles of MicroRNAs in Pancreatic Cancer Diagnosis, Therapy and Prognosis (Review). International Journal of Oncology, 47, 1203-1210. &lt;br&gt;https://doi.org/10.3892/ijo.2015.3129</mixed-citation></ref><ref id="hanspub.34506-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tian, X., Shivapurkar, N., Wu, Z., et al. (2016) Circulating Mi-croRNA Profile Predicts Disease Progression in Patients Receiving Second-Line Treatment of Lapatinib and Cape-citabine for Metastatic Pancreatic Cancer. Oncology Letters, 11, 1645-1650. &lt;br&gt;https://doi.org/10.3892/ol.2016.4101</mixed-citation></ref><ref id="hanspub.34506-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bhagwat, N., Dulmage Jr., K., et al. (2018) An Integrated Flow Cytometry-Based Platform for Isolation and Molecular Characterization of Circulating Tumor Single Cells and Clusters. Scientific Reports, 8, 5035.  
&lt;br&gt;https://doi.org/10.1038/s41598-018-23217-5</mixed-citation></ref><ref id="hanspub.34506-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Y., Zhu, Y. and Yuan, Z. (2016) Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. International Journal of Medical Sciences, 13, 902-913. &lt;br&gt;https://doi.org/10.7150/ijms.16734</mixed-citation></ref><ref id="hanspub.34506-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kolostova, K., Rzechonek, A., Schützner, J.A.N. and Grill, R. (2017) Circulating Tumor Cells as an Auxiliary. In Vivo, 31, 1197-1202. &lt;br&gt;https://doi.org/10.21873/invivo.11190</mixed-citation></ref><ref id="hanspub.34506-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Desjobert, C., El Maï, M., Gérard-Hirne, T., et al. (2015) Combined Analysis of DNA Methylation and Cell Cycle in Cancer Cells. Epigenetics, 10, 82-91. &lt;br&gt;https://doi.org/10.1080/15592294.2014.995542</mixed-citation></ref><ref id="hanspub.34506-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yi, J.M., Guzzetta, A.A., Bailey, V.J., et al. (2013) Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research, 19, 6544-6555. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-12-3224</mixed-citation></ref><ref id="hanspub.34506-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Melo, S.A., Luecke, L.B., Kahlert, C., et al. (2015) Glypican1 Identifies Cancer Exosomes and Facilitates Early Detection of Cancer. Nature, 523, 177-182. &lt;br&gt;https://doi.org/10.1038/nature14581</mixed-citation></ref><ref id="hanspub.34506-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Tan, C., Zhang, H., Peng, B. and Li, K. (2015) Outcome and Costs of Laparoscopic Pancreaticoduodenectomy during the Initial Learning Curve vs Laparotomy. World Journal of Gas-troenterology, 21, 5311-5319. 
&lt;br&gt;https://doi.org/10.3748/wjg.v21.i17.5311</mixed-citation></ref><ref id="hanspub.34506-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Handgraaf, H.J.M., Boonstra, M.C., Van Erkel, A.R., et al. (2014) Current and Future Intraoperative Imaging Strategies to Increase Radical Resection Rates in Pancreatic Cancer Surgery. BioMed Research International, 2014, 1-8. 
&lt;br&gt;https://doi.org/10.1155/2014/890230</mixed-citation></ref><ref id="hanspub.34506-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">de Werra, C., Quarto, G., Aloia, S., et al. (2015) The Use of In-traoperative Ultrasound for Diagnosis and Stadiation in Pancreatic Head Neoformations. International Journal of Surgery, 21, S55-S58.  
&lt;br&gt;https://doi.org/10.1016/j.ijsu.2015.04.091</mixed-citation></ref><ref id="hanspub.34506-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Nelson, D.W., Blanchard, T.H., Causey, M.W., et al. (2013) Examining the Accuracy and Clinical Usefulness of Intraoperative Frozen Section Analysis in the Management of Pancreatic Lesions. The American Journal of Surgery, 205, 613-617. &lt;br&gt;https://doi.org/10.1016/j.amjsurg.2013.01.015</mixed-citation></ref><ref id="hanspub.34506-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Vahrmeijer, A.L., Hutteman, M., van der Vorst, J.R., van de Velde, C.J.H. and Frangioni, J.V. (2013) Image-Guided Cancer Surgery Using Near-Infrared Fluorescence. Na-ture Reviews Clinical Oncology, 10, 507-518. 
&lt;br&gt;https://doi.org/10.1038/nrclinonc.2013.123</mixed-citation></ref><ref id="hanspub.34506-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Yano, S., Hiroshima, Y., Maawy, A., et al. (2015) Col-or-Coding Cancer and Stromal Cells with Genetic Reporters in a Patient-Derived Orthotopic Xenograft (PDOX) Model of Pancreatic Cancer Enhances Fluorescence-Guided Surgery. Cancer Gene Therapy, 22, 344-350. &lt;br&gt;https://doi.org/10.1038/cgt.2015.26</mixed-citation></ref><ref id="hanspub.34506-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Muranaka, T., Kuwatani, M., Komatsu, Y., et al. (2017) Comparison of Efficacy and Toxicity of FOLFIRINOX and Gemcitabine with Nab-Paclitaxel in Unresectable Pancreatic Cancer. Journal of Gastrointestinal Oncology, 8, 566-571.  
&lt;br&gt;https://doi.org/10.21037/jgo.2017.02.02</mixed-citation></ref><ref id="hanspub.34506-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Han, Q., Deng, M., Lv, Y. and Dai, G. (2017) Survival of Patients with Advanced Pancreatic Cancer after Iodine 125 Seeds Implantation Brachytherapy: A Meta-Analysis. Medicine, 96, e5719.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000005719</mixed-citation></ref><ref id="hanspub.34506-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Lauffer, D.C., Kuhn, P.A., Kueng, M., et al. (2018) Pancreatic Cancer: Feasibility and Outcome after Radiochemotherapy with High Dose External Radiotherapy for Non-Resected and R1 Resected Patients. Cureus, 10, 1-7. &lt;br&gt;https://doi.org/10.7759/cureus.c14</mixed-citation></ref><ref id="hanspub.34506-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Ma, N., Wang, Z., Zhao, J., et al. (2017) Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postop-erative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. Medical Science Monitor, 23, 2315-2323. &lt;br&gt;https://doi.org/10.12659/MSM.904393</mixed-citation></ref><ref id="hanspub.34506-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Chiorean, E.G. and Coveler, A.L. (2015) Pancreatic Cancer: Optimizing Treatment Options, New, and Emerging Targeted Therapies. Drug Design, Devel-opment and Therapy, 9, 3529-3545. &lt;br&gt;https://doi.org/10.2147/DDDT.S60328</mixed-citation></ref><ref id="hanspub.34506-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Matsuoka, T. and Yashiro, M. (2016) Molecular Targets for the Treatment of Pancreatic Cancer: Clinical and Experimental Studies. World Journal of Gastroenterology, 22, 776-789. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i2.776</mixed-citation></ref><ref id="hanspub.34506-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Furuse, J., Gemma, A., Ichikawa, W., Okusaka, T., Seki, A. and Ishii, T. (2017) Postmarketing Surveillance Study of Erlotinib plus Gem-citabine for Pancreatic Cancer in Japan: POLARIS Final Analysis. Japanese Journal of Clinical Oncology, 47, 832-839. &lt;br&gt;https://doi.org/10.1093/jjco/hyx075</mixed-citation></ref><ref id="hanspub.34506-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Vogl, T.J., Panahi, B., Albrecht, M.H., et al. (2018) Mi-crowave Ablation of Pancreatic Tumors. Minimally Invasive Therapy &amp; Allied Technologies, 27, 33-40. &lt;br&gt;https://doi.org/10.1080/13645706.2017.1420664</mixed-citation></ref><ref id="hanspub.34506-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Strunk, H.M., Henseler, J., Rauch, M., et al. (2016) Clinical Use of High-Intensity Focused Ultrasound (HIFU) for Tumor and Pain Reduction in Advanced Pancreatic Cancer. RoFo, 188, 662-670.  
&lt;br&gt;https://doi.org/10.1055/s-0042-105517</mixed-citation></ref><ref id="hanspub.34506-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y. (2015) Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer Find the Latest Version: Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. The Journal of Clinical Investigation, 125, 3335-3337. &lt;br&gt;https://doi.org/10.1172/JCI83871</mixed-citation></ref><ref id="hanspub.34506-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Sharpe, M.E. (2018) T-Cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. Toxicologic Pathology, 46, 131-146. &lt;br&gt;https://doi.org/10.1177/0192623317752101</mixed-citation></ref></ref-list></back></article>